Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery
NCT00665457 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3
Last updated 2023-09-13
Summary
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This phase II clinical trial is studying biomarkers and side effects in women receiving chemotherapy and celecoxib for stage II or stage III breast cancer that can be removed by surgery.
Conditions
Interventions
- BIOLOGICAL
- DRUG
- DRUG
-
celecoxib
- DRUG
- DRUG
- DRUG
-
doxorubicin hydrochloride
- GENETIC
-
gene expression analysis
- GENETIC
-
polymorphism analysis
- GENETIC
-
protein expression analysis
- GENETIC
-
reverse transcriptase-polymerase chain reaction
- OTHER
-
imaging biomarker analysis
- OTHER
-
immunohistochemistry staining method
- OTHER
-
laboratory biomarker analysis
- OTHER
-
pharmacogenomic studies
- PROCEDURE
-
dynamic contrast-enhanced magnetic resonance imaging
- PROCEDURE
-
needle biopsy
- PROCEDURE
-
neoadjuvant therapy
- PROCEDURE
-
radiomammography
- PROCEDURE
-
ultrasound imaging
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
University of Nebraska
lead OTHER
Principal Investigators
-
Elizabeth C. Reed, MD · University of Nebraska
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 19 Years
- Max Age
- 120 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-04-15
- Primary Completion
- 2009-07-31
- Completion
- 2009-07-31
Countries
- United States
Study Locations
More Related Trials
-
Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast Cancer
NCT00645866 ·Status: COMPLETED ·Phase: PHASE2
-
AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer
NCT00310089 ·Status: COMPLETED ·Phase: NA
-
An Examination of Predictors of Indicators of Response to Celecoxib in Women Who Have a Diagnosis of Early Breast Cancer
NCT00291122 ·Status: COMPLETED
-
Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer
NCT00005908 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery
NCT00194779 ·Status: COMPLETED ·Phase: PHASE2
-
Studying Biological Markers of Fatigue in Women With Residual Invasive Breast Cancer Enrolled on Clinical Trial NSABP-B-45
NCT00914043 ·Status: WITHDRAWN
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
NCT05020860 ·Status: RECRUITING ·Phase: PHASE2
-
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
NCT01275677 ·Status: COMPLETED ·Phase: PHASE3
-
Studying Tissue Samples From Women Who Underwent Chemotherapy for Lymph Node-Positive Stage II or Stage IIIA Breast Cancer on Clinical Trial CLB-9741 or CLB-9344
NCT00897026 ·Status: COMPLETED
-
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
NCT04081389 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy
NCT05069038 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Effect of Surgery, Radiation Therapy, Chemotherapy, and Hormone Therapy on Biomarkers in Women With Stage I, Stage II, Stage III Breast Cancer, or Ductal Carcinoma In Situ That Can Be Removed By Surgery
NCT00373191 ·Status: COMPLETED
-
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
NCT00353483 ·Status: RECRUITING
-
Docetaxel, Carboplatin, and Pegfilgrastim in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
NCT00107510 ·Status: COMPLETED ·Phase: PHASE2
-
Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer
NCT03628066 ·Status: COMPLETED ·Phase: PHASE2
-
Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
NCT00618657 ·Status: COMPLETED ·Phase: PHASE2
-
Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer
NCT00017095 ·Status: COMPLETED ·Phase: PHASE3
-
Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer
NCT01750073 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer
NCT00005800 ·Status: COMPLETED ·Phase: PHASE2
-
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
NCT02003209 ·Status: COMPLETED ·Phase: PHASE3
-
Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer
NCT00002627 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study of Women With an Early Diagnosis of Breast Cancer, Taking Celecoxib Between the Biopsy and Lumpectomy/Mastectomy
NCT00328432 ·Status: COMPLETED ·Phase: PHASE1
-
Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery
NCT02654119 ·Status: COMPLETED ·Phase: PHASE2
-
Celecoxib and Trastuzumab in Treating Women With Metastatic Breast Cancer
NCT00006381 ·Status: COMPLETED ·Phase: PHASE2
-
Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer
NCT00080626 ·Status: TERMINATED ·Phase: PHASE2